6533b823fe1ef96bd127f50f
RESEARCH PRODUCT
Inhibition of Delayed-Type Hypersensitivity by Cucurbitacin R through the Curbing of Lymphocyte Proliferation and Cytokine Expression by Means of Nuclear Factor AT Translocation to the Nucleus
Miguel Cerdá-nicolásSalvador MáñezJosé Luis RíosIrmgard MerfortRosa M. GinerMaría Del Carmen RecioJosé M. Escandellsubject
Interleukin 2medicine.medical_specialtyT-Lymphocytesmedicine.medical_treatmentAnti-Inflammatory AgentsLymphocyte proliferationBiologyPharmacologyJurkat cellsDrug HypersensitivityJurkat CellsMiceCyclinsInternal medicinemedicineAnimalsHumansHypersensitivity DelayedInterleukin 4Cell ProliferationPharmacologyNFATC Transcription FactorsFootCell CycleIntracellular Signaling Peptides and ProteinsOxazoloneEarNFATCell cycleTriterpenesInterleukin 10EndocrinologyCytokineCytokinesMolecular MedicineDinitrofluorobenzeneFemalemedicine.drugdescription
Cucurbitacin R is known to exhibit an anti-inflammatory effect in different experimental models of inflammation. In this article, we outline the effect of cucurbitacin R on T lymphocyte proliferation, cytokine production, and nuclear factor activation, as well as its influence on various experimental models of delayed-type hypersensitivity (DTH) in mice. Cucurbitacin R reduced the proliferation of phytohemagglutinin A-stimulated human T lymphocytes (IC(50), 18 microM), modifying the cell cycle, as well as the production of cytokines [interleukin (IL)-2, IL-4, IL-10, and especially interferon-gamma] and the induction of the principal cyclins implicated in the cell cycle (A(1), B(1), D(2), and E). These effects are brought on by a novel, selective inhibition of nuclear factor AT (NFAT) by cucurbitacin R, with no concomitant effect on other transcription factors such as activator protein-1. In addition, we tested the in vivo effects of cucurbitacin R in three experimental models of DTH, as well as its effects on T lymphocyte proliferation, the cell cycle, cytokines, and cyclins. Although cucurbitacin R was found to reduce the inflammatory response brought on by both oxazolone and dinitrofluorobenzene, its activity was even more pronounced against sheep red blood cell-induced edema in mouse paws, with a clear reduction in the production of IL-1beta, IL-4, and tumor necrosis factor alpha in the inflamed paw. In conclusion, cucurbitacin R has the potential to be a new immunosuppressive agent with antiproliferative effects through the inhibition of the NFAT with anti-inflammatory activity in DTH reactions.
year | journal | country | edition | language |
---|---|---|---|---|
2009-10-23 | Journal of Pharmacology and Experimental Therapeutics |